Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Roland Rad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6849-9659; OpenAlex author ID A5082231210, A5085203886. Sources: OpenAlex.

Their work

Papers
36 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
193
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 8 papers · 2023: 3 papers · 2024: 1 paper · 2025: 4 papers · 2026: 6 papers

Papers 36

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  3. Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. Co-author DOI 10.1016/j.xcrm.2025.102546↗
  4. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  5. Cross-species single-cell atlases chart progression, therapy-driven remodelling and immune evasion in pancreatic cancer Co-author DOI 10.64898/2026.03.19.712924↗
  6. Modeling pancreatic cancer tumor stroma co-evolution in an in ovo model Co-author DOI 10.64898/2026.06.26.734719↗
  7. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  8. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  9. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
  10. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
  11. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  12. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. Co-author DOI 10.1038/s43018-023-00526-x↗
  13. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-0876↗
  14. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  15. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  16. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  17. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Co-author DOI 10.1038/s43018-021-00326-1↗
  18. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  19. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2020-321397↗
  20. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  21. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  22. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  23. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Co-author DOI 10.1053/j.gastro.2020.09.010↗
  24. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Co-author DOI 10.1053/j.gastro.2021.07.030↗
  25. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  26. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Co-author DOI 10.1002/1878-0261.12835↗
  27. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  28. Loss of Wasl improves pancreatic cancer outcome. Co-author DOI 10.1172/jci.insight.127275↗
  29. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  30. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  31. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Last author DOI 10.1038/nature25459↗
  32. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  33. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Co-author DOI 10.1038/onc.2016.344↗
  34. siRNA-coupled nanoparticles for improved therapeutic targeting of pancreatic cancer. Last author DOI 10.1136/gutjnl-2016-312092↗
  35. A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer. Co-author DOI 10.1038/ng.3164↗
  36. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Co-author DOI 10.1038/nm.3646↗

Closest collaborators

The 25 strongest of 193 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dieter Saur · 29 shared papers, 2014–2026 · strength 3.69
  2. Günter Schneider · 22 shared papers, 2014–2026 · strength 2.55
  3. Maximilian Reichert · 21 shared papers, 2017–2026 · strength 2.48
  4. Roland Michael Schmid · 18 shared papers, 2014–2026 · strength 1.98
  5. Stefanie Bärthel · 9 shared papers, 2022–2026 · strength 1.63
  6. Christian Schneeweis · 11 shared papers, 2018–2026 · strength 1.40
  7. Chiara Falcomatà · 7 shared papers, 2022–2026 · strength 1.22
  8. Matthias Wirth · 11 shared papers, 2017–2026 · strength 1.17
  9. Felix Orben · 8 shared papers, 2020–2026 · strength 1.00
  10. İhsan Ekin Demir · 6 shared papers, 2022–2026 · strength 0.96
  11. Daniele Lucarelli · 5 shared papers, 2022–2026 · strength 0.92
  12. Zonera Hassan · 9 shared papers, 2017–2022 · strength 0.82
  13. Lukas Krauß · 6 shared papers, 2022–2026 · strength 0.81
  14. Carolin Schneider · 6 shared papers, 2022–2026 · strength 0.81
  15. Hana Algül · 6 shared papers, 2020–2026 · strength 0.79
  16. Aristeidis Papargyriou · 6 shared papers, 2020–2025 · strength 0.79
  17. Oliver Holger Krämer · 7 shared papers, 2017–2026 · strength 0.77
  18. Carmen Mota Reyes · 4 shared papers, 2023–2026 · strength 0.68
  19. Sebastian Mueller · 5 shared papers, 2018–2026 · strength 0.67
  20. Guralp Onur Ceyhan · 5 shared papers, 2018–2026 · strength 0.61
  21. H. Carlo Maurer · 4 shared papers, 2021–2026 · strength 0.59
  22. Sebastian Lange · 6 shared papers, 2016–2025 · strength 0.57
  23. Helmut Friess · 4 shared papers, 2021–2026 · strength 0.57
  24. Marina Lesina · 4 shared papers, 2020–2026 · strength 0.56
  25. Elisabeth Heßmann · 4 shared papers, 2021–2026 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.